The following descriptions of new molecular entities approved in 2008-2009 summarize each new drug's clinical and pharmacologic profile, as well as selected pharmacokinetic, adverse-reaction,
drug-interaction, and dosing data.
With pharmacists moving more toward a role of medication therapy
management versus dispensing, it is crucial for the practitioner to
keep up with the latest guidelines.
New molecular entities are new drug
products containing as their active ingredient a chemical substance
marketed for the first time in the United States.
Understanding the relative advantages and disadvantages of OTC antacids, H2 antagonists, and proton pump inhibitors allows the pharmacist to provide lasting relief for patients.
Three of the vaccines against the H1N1 virus are available in injectable form and one isavailable in nasal spray form; all four vaccines are monovalent. The seasonal influenza vaccine for the 2009-2010 season is atrivalent-inactivated vaccine containing A/Brisbane/59/2007 H1N1-like,A/Brisbane 10/2007 H3N2-like/B/Brisbane/60/2008-like antigens.